Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies

被引:26
|
作者
Yang, Shuanghui [1 ,2 ]
Li, Huan [2 ,3 ]
Xu, Ling [2 ,4 ]
Deng, Zhenhan [5 ]
Han, Wei [2 ]
Liu, Yanting [2 ]
Jiang, Wenqi [2 ]
Zu, Youli [2 ]
机构
[1] Cent South Univ, Xiangya Hosp, Dept Hematol, Changsha 410008, Hunan, Peoples R China
[2] Houston Methodist Hosp, Dept Pathol & Genom Med, 6565 Fannin St, Houston, TX 77030 USA
[3] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China
[4] Jinan Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou 510632, Guangdong, Peoples R China
[5] Cent South Univ, Xiangya Hosp, Dept Orthopaed, Changsha 410008, Hunan, Peoples R China
来源
MOLECULAR THERAPY-NUCLEIC ACIDS | 2018年 / 13卷
关键词
B-CELL LYMPHOMA; ANTIBODY-TARGETED CHEMOTHERAPY; CHRONIC LYMPHOCYTIC-LEUKEMIA; FLOW-CYTOMETRIC ANALYSIS; CANCER-CELLS; BETA-ARRESTINS; DNA APTAMER; MONOCLONAL-ANTIBODY; CD30; EXPRESSION; DRUG CONJUGATE;
D O I
10.1016/j.omtn.2018.08.023
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Precision medicine has recently emerged as a promising strategy for cancer therapy because it not only specifically targets cancer cells but it also does not have adverse effects on normal cells. Oligonucleotide aptamers are a class of small molecule ligands that can specifically bind to their targets on cell surfaces with high affinity. Aptamers have great potential in precision cancer therapy due to their unique physical, chemical, and biological properties. Therefore, aptamer technology has been widely investigated for biomedical and clinical applications. This review focuses on the potential applications of aptamer technology as a new tool for precision treatment of hematological malignancies, including leukemia, lymphoma, and multiple myeloma.
引用
收藏
页码:164 / 175
页数:12
相关论文
共 50 条
  • [1] Aptamer-Mediated Cancer Gene Therapy
    Xiang, Dongxi
    Shigdar, Sarah
    Qiao, Greg
    Zhou, Shu-Feng
    Li, Yong
    Wei, Ming Q.
    Qiao, Liang
    Shamaileh, Hadi Al.
    Zhu, Yimin
    Zheng, Conglong
    Pu, Chunwen
    Duan, Wei
    CURRENT GENE THERAPY, 2015, 15 (02) : 109 - 119
  • [2] DNA Aptamer-Mediated Cell Targeting
    Xiong, Xiangling
    Liu, Haipeng
    Zhao, Zilong
    Altman, Meghan B.
    Lopez-Colon, Dalia
    Yang, Chaoyong James
    Chang, Lung-Ji
    Liu, Chen
    Tan, Weihong
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2013, 52 (05) : 1472 - 1476
  • [3] Nucleic Acid Aptamer-Mediated Drug Delivery for Targeted Cancer Therapy
    Zhu, Huijie
    Li, Jin
    Zhang, Xiao-Bing
    Ye, Mao
    Tan, Weihong
    CHEMMEDCHEM, 2015, 10 (01) : 39 - 45
  • [4] Aptamer-Mediated Targeted Delivery of Large RNA
    Alam, Khalid K.
    Porciani, David
    Hill, Kyle J.
    Burke, Donald H.
    MOLECULAR THERAPY, 2015, 23 : S196 - S196
  • [5] Research Progress of Aptamer-mediated Tumor Immunotherapy
    Zhou Ling-Li
    Ye Mao
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2022, 49 (06) : 1036 - 1044
  • [6] Aptamer-Mediated Targeted Delivery of Therapeutics: An Update
    Catuogno, Silvia
    Esposito, Carla L.
    de Franciscis, Vittorio
    PHARMACEUTICALS, 2016, 9 (04)
  • [7] Aptamer-Mediated Nanotheranostics for Cancer Treatment: A Review
    Ravichandran, Gayathri
    Rengan, Aravind Kumar
    ACS APPLIED NANO MATERIALS, 2020, 3 (10) : 9542 - 9559
  • [8] Aptamer-mediated drug delivery; [Aptamer-vermitteltes drug delivery]
    Magbanua E.
    Hahn U.
    BIOspektrum, 2016, 22 (4) : 378 - 381
  • [9] Smart ligand: Aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy
    Li, Xin
    Zhao, Qinghe
    Qiu, Liyan
    JOURNAL OF CONTROLLED RELEASE, 2013, 171 (02) : 152 - 162
  • [10] Design and Evaluation of RNA Aptamer-Mediated Delivery of C/EBPβ siRNA for Oncological Therapy
    Vasconcelos, D.
    Sodergren, M. H.
    Reebye, V.
    Vasara, J.
    Song, M. S.
    Holm, K.
    Khorsandi, S. E.
    Rossi, J.
    Habib, N.
    Huang, K. W.
    JOURNAL OF NUCLEIC ACIDS, 2025, 2025 (01)